RxDoctor Payments Data

Jessica Buriak, DO

Internal Medicine · Butler, PANPI 1134417801

Payments from drug & device makers

$646in general payments, 2019–2025

Across 39 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$213
  • Novo Nordisk$140
  • Amgen$69
  • GSK$51
  • Astellas Pharma US Inc$41
  • Inspire Medical Systems, Inc.$31
  • plus $101 from 6 others

What the payments were for

  • Food & beverage$646100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie15$213
Novo Nordisk8$140
Amgen4$69
GSK3$51
Astellas Pharma US Inc2$41
Inspire Medical Systems, Inc.1$31
Medtronic1$25
Boehringer Ingelheim1$18
Cipher Pharmaceuticals US LLC1$16
Merck1$16
AstraZeneca1$15
Boston Scientific1$12

How this compares

$646 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$115,223
Medicare patients
159
Services billed
1,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide133$167,704
EliquisApixaban114$97,723
ProliaDenosumab37$63,597
JardianceEmpagliflozin34$45,004
Breo ElliptaFluticasone/Vilanterol75$33,289
TradjentaLinagliptin33$23,020
TrulicityDulaglutide16$17,418
XareltoRivaroxaban16$14,036
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,730
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$8,509
FarxigaDapagliflozin Propanediol13$7,296
Arnuity ElliptaFluticasone Furoate16$5,868
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$5,291
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$5,201
Atorvastatin Calcium517$5,157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$140$167,704133 claims
Boehringer IngelheimJardiance, Tradjenta$18$68,02467 claims
AmgenProlia$69$63,59737 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$51$52,887105 claims
AstraZenecaFarxiga$15$7,29613 claims
AbbVieSynthroid$213$5,14064 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →